SG11201809527UA - Methods of treating circadian rhythm sleep disorders - Google Patents
Methods of treating circadian rhythm sleep disordersInfo
- Publication number
- SG11201809527UA SG11201809527UA SG11201809527UA SG11201809527UA SG11201809527UA SG 11201809527U A SG11201809527U A SG 11201809527UA SG 11201809527U A SG11201809527U A SG 11201809527UA SG 11201809527U A SG11201809527U A SG 11201809527UA SG 11201809527U A SG11201809527U A SG 11201809527UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- vehicle
- methods
- october
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111111111111111111111111111111111111011111011H1101111001111111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/197160 Al 16 November 2017 (16.11.2017) WIPO I PCT (51) International Patent Classification: Margaret [US/US]; 18 Eastdale Road, White Plains, NY A61K 31/501 (2006.01) A61P 25/28 (2006.01) 10605 (US). SATLIN, Andrew [US/US]; 350 Long Hill A61P 43/00 (2006.01) Drive, Short Hills, NJ 07078 (US). (21) International Application Number: (74) Agent: MACALPINE, Jill, K.; Finnegan, Henderson, PCT/US2017/032228 Farabow, Garrett & Dunner, LLP, 901 New York Avenue, (22) International Filing Date: NW, Washington, DC 20001 (US). 11 May 2017 (11.05.2017) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (26) Publication Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (30) Priority Data: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/335,599 12 May 2016 (12.05.2016) US HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, 62/335,611 12 May 2016 (12.05.2016) US KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 62/413,976 27 October 2016 (27.10.2016) US MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 62/414,599 28 October 2016 (28.10.2016) US PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 62/414,606 28 October 2016 (28.10.2016) US SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant: EISAI R&D MANAGEMENT CO., LTD. (84) Designated States (unless otherwise indicated, for every _ [JP/JP]; 6-10 Koishikawa, 4-chome, Bunkyo-ku, Tokyo, kind of regional protection available): ARIPO (BW, GH, 112-8088 (JP). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Inventors; and UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = (72) (71) Applicants: BEUCKMANN, Carsten, T. [DE/JP]; 5-1-3 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Tokodai, Tsukuba, Ibaraki, 300-2635 (JP). MOLINE, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, = = = (54) Title: METHODS OF TREATING CIRCADIAN RHYTHM SLEEP DISORDERS = FIG. 'IA = = 80 = Ti ter 70 =W a kefulness = 60 o RI vehicle = 4 1 4, 9 60 ...e x.. = in RI 3 mg/kg = 0 40 E --- 30 . / // 7 a RI 30 mg/kg to P8 vehicle _ _ ,,,i) = .4 20 EPS 3 mg/kg 10 ta P8 30 mg/kg — 1-1 11\" 0.612 ZT 12-24 .4 0 1-1 Data represent least square means and standard errors IN 01 1-1 *: significant difference compared to R1 vehicle cohort (P<0.05, linear mixed model with Kenward-Roger) t: significant difference compared to P8 vehicle cohort (P<0.05, linear mixed model with Kenward-Roger) IN 1-1 0 (57) : Methods of treating irregular sleep-wake rhythm disorder in subjects and compositions for use in the same are disclosed. ei O [Continued on next page] WO 2017/197160 Al DIII MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662335599P | 2016-05-12 | 2016-05-12 | |
| US201662335611P | 2016-05-12 | 2016-05-12 | |
| US201662413976P | 2016-10-27 | 2016-10-27 | |
| US201662414606P | 2016-10-28 | 2016-10-28 | |
| US201662414599P | 2016-10-28 | 2016-10-28 | |
| PCT/US2017/032228 WO2017197160A1 (en) | 2016-05-12 | 2017-05-11 | Methods of treating circadian rhythm sleep disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809527UA true SG11201809527UA (en) | 2018-11-29 |
Family
ID=58745465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809527UA SG11201809527UA (en) | 2016-05-12 | 2017-05-11 | Methods of treating circadian rhythm sleep disorders |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11096941B2 (en) |
| EP (2) | EP3454859B1 (en) |
| JP (2) | JP6888026B2 (en) |
| KR (2) | KR20230043227A (en) |
| CN (1) | CN109640998A (en) |
| AU (2) | AU2017264871B2 (en) |
| BR (1) | BR112018073037A2 (en) |
| CA (1) | CA3022068A1 (en) |
| ES (1) | ES2904625T3 (en) |
| IL (2) | IL291791A (en) |
| MX (1) | MX2018013663A (en) |
| RU (1) | RU2763493C2 (en) |
| SG (1) | SG11201809527UA (en) |
| TW (1) | TWI795359B (en) |
| WO (1) | WO2017197160A1 (en) |
| ZA (1) | ZA201807903B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2763493C2 (en) * | 2016-05-12 | 2021-12-29 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Methods for treatment of disorders of circadian sleep rhythm |
| CN114096251A (en) * | 2019-06-26 | 2022-02-25 | 卫材R&D管理有限公司 | Leibo leisheng for treating sleep problems |
| WO2020263253A1 (en) * | 2019-06-26 | 2020-12-30 | Moline Margaret | Lemborexant for treating sleep issues |
| JP2022547388A (en) * | 2019-09-13 | 2022-11-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Pharmaceutical composition for treating insomnia |
| US20240010629A1 (en) * | 2019-12-11 | 2024-01-11 | Teva Czech Industries S.R.O | Solid state form of lemborexant |
| CA3164198A1 (en) * | 2020-01-16 | 2021-07-22 | Eisai R&D Management Co., Ltd. | Drug substance of lemborexant and medicinal composition comprising same |
| CN111450076A (en) * | 2020-05-25 | 2020-07-28 | 安徽省逸欣铭医药科技有限公司 | L emborexant soft capsule composition and preparation method thereof |
| CN117769423A (en) * | 2021-07-26 | 2024-03-26 | 卫材R&D管理有限公司 | Lebo Lei Sheng for use in a method of treating irregular sleep wake rhythm disorders and circadian rhythm sleep disorders associated with neurodegenerative diseases |
| CN116421605A (en) * | 2022-01-04 | 2023-07-14 | 中国科学院脑科学与智能技术卓越创新中心 | Use of ISX-9 in the treatment of circadian amplitude decline and sleep disorders associated with aging |
| WO2024064897A1 (en) | 2022-09-23 | 2024-03-28 | Eisai R&D Management Co., Ltd. | Methods of reducing neurodegeneration associated with neurodegenerative diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005082143A1 (en) * | 2004-02-20 | 2005-09-09 | Lifescape Biosciences Incorporated | Compositions and methods for sleep regulation |
| ES2339822T3 (en) * | 2006-08-28 | 2010-05-25 | Actelion Pharmaceuticals Ltd. | DERIVATIVES OF 1,4,5,6,7,8-HEXAHIDRO-1,2,5-TRIAZA-AZULEN AS ANTAGONISTS OF THE OREXINE RECEIVER. |
| JP4944286B1 (en) | 2010-09-22 | 2012-05-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Cyclopropane compound |
| WO2013119639A1 (en) * | 2012-02-07 | 2013-08-15 | Eolas Therapeutics, Inc. | Substituted prolines / piperidines as orexin receptor antagonists |
| MX2017004950A (en) * | 2014-10-23 | 2018-01-16 | Eisai R&D Man Co Ltd | Compositions and methods for treating insomnia. |
| RU2763493C2 (en) | 2016-05-12 | 2021-12-29 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Methods for treatment of disorders of circadian sleep rhythm |
-
2017
- 2017-05-11 RU RU2018143809A patent/RU2763493C2/en active
- 2017-05-11 AU AU2017264871A patent/AU2017264871B2/en active Active
- 2017-05-11 CN CN201780039758.8A patent/CN109640998A/en active Pending
- 2017-05-11 SG SG11201809527UA patent/SG11201809527UA/en unknown
- 2017-05-11 KR KR1020237009013A patent/KR20230043227A/en not_active Application Discontinuation
- 2017-05-11 EP EP17725084.2A patent/EP3454859B1/en active Active
- 2017-05-11 CA CA3022068A patent/CA3022068A1/en active Pending
- 2017-05-11 BR BR112018073037-8A patent/BR112018073037A2/en active Search and Examination
- 2017-05-11 IL IL291791A patent/IL291791A/en unknown
- 2017-05-11 WO PCT/US2017/032228 patent/WO2017197160A1/en unknown
- 2017-05-11 JP JP2018558728A patent/JP6888026B2/en active Active
- 2017-05-11 ES ES17725084T patent/ES2904625T3/en active Active
- 2017-05-11 KR KR1020187035708A patent/KR102511855B1/en active IP Right Grant
- 2017-05-11 US US16/300,335 patent/US11096941B2/en active Active
- 2017-05-11 MX MX2018013663A patent/MX2018013663A/en unknown
- 2017-05-11 EP EP21208238.2A patent/EP4056180A1/en active Pending
- 2017-05-12 TW TW106115904A patent/TWI795359B/en active
-
2018
- 2018-11-06 IL IL262803A patent/IL262803B/en unknown
- 2018-11-22 ZA ZA2018/07903A patent/ZA201807903B/en unknown
-
2021
- 2021-05-19 JP JP2021084719A patent/JP7150096B2/en active Active
- 2021-07-27 US US17/443,650 patent/US20210353625A1/en active Pending
-
2023
- 2023-05-31 AU AU2023203418A patent/AU2023203418A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI795359B (en) | 2023-03-11 |
| US20200179382A1 (en) | 2020-06-11 |
| US20210353625A1 (en) | 2021-11-18 |
| JP7150096B2 (en) | 2022-10-07 |
| IL291791A (en) | 2022-06-01 |
| MX2018013663A (en) | 2019-07-18 |
| AU2017264871B2 (en) | 2023-03-16 |
| EP3454859B1 (en) | 2021-12-01 |
| IL262803B (en) | 2022-05-01 |
| AU2023203418A1 (en) | 2023-06-29 |
| EP3454859A1 (en) | 2019-03-20 |
| KR20190013820A (en) | 2019-02-11 |
| RU2018143809A3 (en) | 2020-09-17 |
| WO2017197160A1 (en) | 2017-11-16 |
| EP4056180A1 (en) | 2022-09-14 |
| KR102511855B1 (en) | 2023-03-20 |
| CA3022068A1 (en) | 2017-11-16 |
| JP6888026B2 (en) | 2021-06-16 |
| BR112018073037A2 (en) | 2019-02-26 |
| KR20230043227A (en) | 2023-03-30 |
| TW201740952A (en) | 2017-12-01 |
| ES2904625T3 (en) | 2022-04-05 |
| US11096941B2 (en) | 2021-08-24 |
| IL262803A (en) | 2018-12-31 |
| RU2763493C2 (en) | 2021-12-29 |
| CN109640998A (en) | 2019-04-16 |
| AU2017264871A1 (en) | 2018-11-15 |
| JP2019518732A (en) | 2019-07-04 |
| JP2021120410A (en) | 2021-08-19 |
| RU2018143809A (en) | 2020-06-15 |
| ZA201807903B (en) | 2021-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809527UA (en) | Methods of treating circadian rhythm sleep disorders | |
| SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201805828YA (en) | Method of treating c3 glomerulopathy | |
| SG11201906161VA (en) | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201805888SA (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
| SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
| SG11201901834WA (en) | Micrornas as biomarkers for endometriosis | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201407417VA (en) | Encoding and reconstruction of residual data based on support information | |
| SG11201907196YA (en) | Composition and methods for preventing radiation injury and promoting tissue regeneration | |
| SG11201805052YA (en) | Therapeutic methods using erythrocytes | |
| SG11201903032SA (en) | Methods and compositions related to nk cell and anti-pdl1 cancer therapies | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201903076QA (en) | Carbamoyl phenylalaninol compounds and uses therof | |
| SG11201805771XA (en) | Systems and methods for preparation of platelets | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201900486WA (en) | Treatment and prevention of sleep disorders | |
| SG11201804220SA (en) | Activated stem cells and systemic treatment methods for infected wounds | |
| SG11201804440XA (en) | Chemical reprogramming of human glial cells into neurons with small molecule cocktail | |
| SG11201908513RA (en) | Peptides for treatment of diabetes | |
| SG11201803816RA (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease |